EpiVax Oncology Announces Three Abstracts Accepted for Presentation at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019)

NEW YORK--()--EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced that three abstracts highlighting its Ancer™ platform have been accepted for presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting from November 6-10, 2019 in National Harbor, Maryland.

Details on the three posters to be presented as part of the regular submissions are below:

Title:

Integrating CD8 and CD4 effector neo-epitope content with regulatory T cell epitope exclusion is a superior prognostic biomarker for bladder cancer patient compared to their tumor mutation burden

Author:

Richard et al.

Poster #:

P74

Presentation Date/Time:

November 9, 2019, 7:00 am - 8:30 pm

 

Title:

Highly efficient selection of tumor neoantigens improves therapeutic cancer vaccine efficacy

Author:

Princiotta et al.

Poster #:

P684

Presentation Date/Time:

November 9, 2019, 7:00 am - 8:30 pm

 

Title:

Lysosomal-associated membrane protein-1-targeting of a poly-neoepitope DNA vaccine elicits potent immune responses and inhibits tumor growth

Author:

Sinha et al.

Poster #:

P688

Presentation Date/Time:

November 9, 2019, 7:00 am - 8:30 pm

“We are excited to present the new data we have generated, which demonstrate the superiority and versatility of our Neo-Epitope prediction platform, Ancer™, for enabling the next generation of cancer immunotherapies, whether they are based on peptides, DNA, RNA or cellular materials,” said EpiVax Oncology CEO, Gad Berdugo, MSc Eng., MBA.

About EpiVax Oncology, Inc.

EpiVax Oncology, Inc. is a privately held biotechnology company focusing on developing precision cancer immunotherapies based in New York City, NY. Incorporated in 2017, EpiVax Oncology is a spin-out of EpiVax Inc., a company founded by Dr. Annie De Groot and Mr. Bill Martin in 1998. EpiVax Oncology is leveraging EpiVax's 20 years of experience in designing commercial-grade immunoinformatic tools, to advance its personalized therapeutic cancer vaccine development program. EpiVax Oncology's personalized immunotherapy design platform, Ancer™, incorporates the world-class EpiMatrix® system and the innovative JanusMatrix™ tool, which were exclusively licensed to EpiVax Oncology by EpiVax. More information about EpiVax Oncology is available at www.epivaxoncology.com.

About Ancer™

​EpiVax Oncology's Ancer™ neoantigen prediction platform, leverages EpiVax’s EpiMatrix® and JanusMatrix™ algorithms, state-of-the-art tools that have been externally validated in several prospective vaccine studies and that are broadly utilized worldwide by pharmaceutical and biotechnology companies. The Ancer™ in silico platform is powered by machine learning based algorithms that prioritize both CD8 and CD4 T cell neoepitopes. Ancer™ enables the rapid, in silico, discovery and removal of inhibitory “Self-Like” Treg neoepitopes; it is designed to enable the discovery of highly immunogenic neoantigens for precision cancer immunotherapies.

Contacts

EpiVax Oncology, Inc.
Gad Berdugo, CEO
Tel: + 1.646.905.3964
Email: gberdugo@epivaxonco.com

Social Media Profiles

Contacts

EpiVax Oncology, Inc.
Gad Berdugo, CEO
Tel: + 1.646.905.3964
Email: gberdugo@epivaxonco.com